GMiA welcomes ‘a’ flagging of biosimilars

The Generic Medicines Industry Association has welcomed the PBAC's decision to consider “a” flagging of biosimilars, and to list biosimilar insulin (Basaglar) on the PBS. Basaglar is the first biosimilar insulin to be approved in Australia, providing an alternative, affordable treatment option for patients suffering from diabetes. “Australian patients are now able to benefit from